Recent in vitro data indicate that gallium may also have potential for the treatment of HIV infection. Titan believes gallium maltolate may unlock the therapeutic potential of gallium, by providing a unique orally active formulation for treatment of cancer and other diseases. Recent Phase I studies of gallium maltolate have demonstrated a good safety profile, with attainment of potentially therapeutic serum drug levels, and pharmacokinetics that support twice a day or once a day dosing. Gallium maltolate may provide the best practical means for utilizing the novel anti-cancer activity of gallium, and we look forward to initiating further clinical testing. Titan Pharmaceuticals, Inc. is a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer and other serious and life-threatening diseases.
Titan now has nine products in development, with seven in clinical testing.
Titan is acquiring the product through the acquisition of GeoMed, Inc. a privately held California company founded for development of the agent. The completion of the acquisition is subject to customary closing conditions. No part of this publication may be redistributed in any form without prior permission. Terms and conditions for users . Privacy policy .